Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfadoxine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CCR4 | P51679 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfadoxine SCHEMBL29390814 | 0.95 | ESR1 (1.00) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL41069 | 0.95 | ESR1 (1.00) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL28436237 | 0.94 | ESR1 (0.97) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL27856131 | 0.94 | ESR1 (0.97) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL28359083 | 0.94 | ESR1 (0.97) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL28537335 | 0.94 | ESR1 (0.97) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL28122268 | 0.89 | ESR1 (0.88) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL30005494 | 0.88 | ESR1 (0.86) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfadoxine SCHEMBL28198178 | 0.86 | ESR1 (0.82) | ESR1MEN1KMT2ACYP2C19LMNA | |
| Sulfalene SCHEMBL28086248 | 0.84 | MEN1 (0.90) | ESR1MEN1KMT2ACYP2C19CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112020562-A | CRISPR-Effector System-based diagnostics | 博德研究所 | 2020-12-01 | — | — | CN | disclosed |
| CN-111836903-A | Multiple diagnostics based on CRISPR effector systems | 博德研究所 | 2020-10-27 | — | — | CN | disclosed |
| CN-111630162-A | CRISPR-Effector System-based diagnostics | 博德研究所 | 2020-09-04 | — | — | CN | disclosed |
| EP-3692367-A1 | DIAGNOSTIC MEANS FOR THE DETECTION AND/OR QUANTIFICATION OF A PLURALITY OF ANALYTES PRESENT IN A SAMPLE | Unisensor (BE) | 2020-08-12 | — | — | EP | disclosed |
| CN-111448311-A | Multi-effector CRISPR-based diagnostic systems | 博德研究所 | 2020-07-24 | — | — | CN | disclosed |
| CN-111108220-A | CRISPR-Effector System-based diagnostics for Virus detection | 博德研究所 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019068806-A1 | DIAGNOSTIC MEANS FOR THE DETECTION AND/OR QUANTIFICATION OF A PLURALITY OF ANALYTES PRESENT IN A SAMPLE | UNISENSOR (BE) | 2019-04-11 | — | — | WO | disclosed |
| US-8383154-B2 | Swellable dosage form comprising gellan gum | EGALET A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| US-8383155-B2 | Swellable dosage form comprising gellan gum | EGALET A/S (DK) | 2013-02-26 | — | — | US | disclosed |
| US-20120039969-A1 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | EGALET A/S | 2012-02-16 | — | — | US | disclosed |
| EP-1758557-B1 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | EGALET LTD (GB) | 2011-07-13 | — | — | EP | disclosed |
| EP-2258349-A2 | Swellable dosage form comprising gellan gum | Egalet A/S (DK) | 2010-12-08 | — | — | EP | disclosed |
| US-7670631-B2 | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. (PT) | 2010-03-02 | — | — | US | disclosed |
| US-20080299199-A1 | Swellable Dosage Form Comprising Gellan Gum | EGALET A/S | 2008-12-04 | — | — | US | disclosed |
| EP-1758557-A2 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | Egalet A/S (DK) | 2007-03-07 | — | — | EP | disclosed |
| EP-1601378-A2 | A METHOD FOR THE PREVENTION OF MALARIA INFECTION OF HUMANS BY HEPATOCYTE GROWTH FACTOR ANTAGONISTS | Instituto Gulbenkian de Ciencia (PT) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005107713-A2 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | EGALET A/S (DK) | 2005-11-17 | — | — | WO | disclosed |
| WO-2004080420-A2 | A METHOD FOR THE PREVENTION OF MALARIA INFECTION OF HUMANS BY HEPATOCYTE GROWTH FACTOR ANTAGONISTS | INSTITUTO GULBENKIAN DE CIENCIA (PT) | 2004-09-23 | — | — | WO | disclosed |
| US-20040185050-A1 | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists | ALFAMA - INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOS FARMACEUTICOS LDA. (PT) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039969-A1 | SWELLABLE DOSAGE FORM COMPRISING GELLAN GUM | PUF60, COG6, GP6 | ESR1 4843/4885MEN1 1971/4885KMT2A 3976/4885 |
| US-20080299199-A1 | Swellable Dosage Form Comprising Gellan Gum | GP6, PUF60, SELL | ESR1 4796/4885MEN1 2890/4885KMT2A 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.